Opportunity Overview
<p>The purpose of this program is to expand access to medications for opioid use disorder, increasing availability of treatment and recovery for individuals with opioid use disorder, and to reduce illicit opioid use and prescription opioid misuse and overdose. </p>
Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | Substance Abuse and Mental Health Services Adminis |
|---|---|
| Country | United States |
| Category | Pharmaceuticals |
| Estimated value | $68.2M |
| NAICS | 93.490 |
| Published | July 01, 2026 |
| Procurement stage | Active solicitation |
| Closed | July 27, 2026 |
| Status | Closed — no longer accepting responses |
| Official source | View original notice |
| Last verified | August 12, 2026 |
Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.
Browse Similar Open Opportunities in United States
See every United States Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United States Pharmaceuticals intelligence report in your inbox
A personalized report on United States Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.